U.S. BioDefense Seeks To Manufacture Roche’s Tamiflu
This article was originally published in The Pink Sheet Daily
Executive Summary
Department of Defense contractor says details of how Roche will sublicense manufacturing responsibilities for the antiviral remain undecided.
You may also be interested in...
Ranbaxy Estimates Production Capacity For Generic Tamiflu
The generics firm said it will be capable of producing the Roche antiviral’s active pharmaceutical ingredient at a rate of 22 tons per annum.
Ranbaxy Estimates Production Capacity For Generic Tamiflu
The generics firm said it will be capable of producing the Roche antiviral’s active pharmaceutical ingredient at a rate of 22 tons per annum.
Roche To Meet With Generic Firms On Tamiflu Rights After Intervention From Senators
Roche agrees to meet with Teva, Mylan, Ranbaxy and Barr to discuss granting manufacturing rights for Tamiflu in order to meet growing global demand for the avian flu antiviral.